Sanofi says it may look at next generation of weight loss drugs: #JPM24
SAN FRANCISCO — Sanofi might not be done with the weight loss space after all.
After its own GLP-1 drug failed a mid-stage trial almost half a decade ago, the French drugmaker missed out on what has become the biggest new drug category of the decade. On Wednesday at the JP Morgan Healthcare Conference, top executives at the company said they could look at potential next-generation products in the years to come that could be more targeted or have better side effects.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.